197 related articles for article (PubMed ID: 28244980)
21. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
23. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia.
Sekiya Y; Xu Y; Muramatsu H; Okuno Y; Narita A; Suzuki K; Wang X; Kawashima N; Sakaguchi H; Yoshida N; Hama A; Takahashi Y; Kato K; Kojima S
Br J Haematol; 2017 Jan; 176(2):248-257. PubMed ID: 27861730
[TBL] [Abstract][Full Text] [Related]
25. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.
Pemmaraju N; Kantarjian H; Jorgensen JL; Jabbour E; Jain N; Thomas D; O'Brien S; Wang X; Huang X; Wang SA; Konopleva M; Konoplev S; Kadia T; Garris R; Pierce S; Garcia-Manero G; Cortes J; Ravandi F
Am J Hematol; 2017 Mar; 92(3):279-285. PubMed ID: 28052371
[TBL] [Abstract][Full Text] [Related]
26. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
Flohr T; Schrauder A; Cazzaniga G; Panzer-Grümayer R; van der Velden V; Fischer S; Stanulla M; Basso G; Niggli FK; Schäfer BW; Sutton R; Koehler R; Zimmermann M; Valsecchi MG; Gadner H; Masera G; Schrappe M; van Dongen JJ; Biondi A; Bartram CR;
Leukemia; 2008 Apr; 22(4):771-82. PubMed ID: 18239620
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia.
Goulden N; Bader P; Van Der Velden V; Moppett J; Schilham M; Masden HO; Krejci O; Kreyenberg H; Lankester A; Révész T; Klingebiel T; Van Dongen J
Br J Haematol; 2003 Jul; 122(1):24-9. PubMed ID: 12823342
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
29. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
30. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.
Bader P; Hancock J; Kreyenberg H; Goulden NJ; Niethammer D; Oakhill A; Steward CG; Handgretinger R; Beck JF; Klingebiel T
Leukemia; 2002 Sep; 16(9):1668-72. PubMed ID: 12200679
[TBL] [Abstract][Full Text] [Related]
31. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
32. Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react.
Pochon C; Oger E; Michel G; Dalle JH; Salmon A; Nelken B; Bertrand Y; Cavé H; Cayuela JM; Grardel N; Macintyre E; Margueritte G; Méchinaud F; Rohrlich P; Paillard C; Demeocq F; Schneider P; Plantaz D; Poirée M; Eliaou JF; Semana G; Drunat S; Jonveaux P; Bordigoni P; Gandemer V
Br J Haematol; 2015 Apr; 169(2):249-61. PubMed ID: 25522886
[TBL] [Abstract][Full Text] [Related]
33. [Real-time quantitative study of minimal residual disease in childhood B cell acute lymphoblastic leukemia].
Jia YP; Liu GL; Zhang LP
Zhonghua Er Ke Za Zhi; 2004 Aug; 42(8):600-4. PubMed ID: 15347448
[TBL] [Abstract][Full Text] [Related]
34. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
35. Impact of pretransplant minimal residual disease on the post-transplant outcome of pediatric acute lymphoblastic leukemia.
Umeda K; Hiramatsu H; Kawaguchi K; Iwai A; Mikami M; Nodomi S; Saida S; Heike T; Ohomori K; Adachi S
Pediatr Transplant; 2016 Aug; 20(5):692-6. PubMed ID: 27256540
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
39. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
[TBL] [Abstract][Full Text] [Related]
40. Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia.
Wethmar K; Matern S; Eßeling E; Angenendt L; Pfeifer H; Brüggemann M; Stelmach P; Call S; Albring JC; Mikesch JH; Reicherts C; Groth C; Schliemann C; Berdel WE; Lenz G; Stelljes M
Bone Marrow Transplant; 2020 Jul; 55(7):1410-1420. PubMed ID: 32001801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
